Interaction Guide · Research summary

Can I take Hypericum Perforatum with Tranylcypromine?

Review Hypericum Perforatum with Tranylcypromine: possible adverse effects, preparation details, evidence limits, and sources.

Prepared by Dr. Edward M.Kim, PharmD · Clinical Director, SupplementSafety editorial team

Research summary published · Prepared · Editorial update

The short answer

Avoid adding St. John's wort to tranylcypromine. Both can affect serotonin, and the combination raises concern for serious serotonin toxicity. Do not replace prescribed treatment or try to manage the interaction by spacing doses yourself.

What this answer covers

Oral Hypericum perforatum preparations used for mood symptoms with oral MAOI treatment. Other botanical species, topical preparations and specific extract strengths are not assumed to be equivalent.

Supplement or preparation
Hypericum perforatum
Medication ingredient
tranylcypromine

Why a mood supplement matters

St. John's wort has pharmacologic effects and can interact with antidepressants. The relevant concern here is an added serotonin effect, not the assumption that every medicine is affected through the same drug-metabolism pathway.

How direct is the evidence?

The tranylcypromine label names St. John's wort in its warning. That is a clear prescribing precaution, but it does not mean a trial has measured the risk for every extract.

Do not substitute a few hours of spacing

Changing the time of a supplement does not remove its pharmacologic effects. If you want to change depression treatment, discuss the specific products and any required medication-free interval with the prescriber managing the MAOI.

Recognize a serious reaction

New agitation or confusion together with fever, heavy sweating, diarrhea, tremor, muscle stiffness or jerking can signal serotonin toxicity. Seek urgent medical assessment and provide the complete list of medicines and supplements.

Evidence and practical considerations

Side effects & toxicity

PARNATE explicitly names St. John's wort among serotonergic agents in its serotonin-syndrome warning. No exact-pair controlled risk estimate was identified.

Exact scope
Oral Hypericum perforatum preparations used for mood symptoms with oral MAOI treatment. Other botanical species, topical preparations and specific extract strengths are not assumed to be equivalent. with Oral tranylcypromine tablets; current sulfate-tablet labeling uses the named active ingredient.
Medication form and route
oral

What remains uncertain

  • The warning is label- and pharmacology-supported. This targeted search did not verify an exact-pair clinical case establishing the frequency of serotonin syndrome.

Factors that may matter: Exact supplement preparation and complete concomitant-medication list require assessment..

Research conclusion: supported with conditions · Evidence assessment: moderate

Read the supporting source summaries

Source 1: Current U.S. prescribing information

dailymed.nlm.nih.gov · Source check Sep 10, 2026

Population: Patients prescribed oral tranylcypromine sulfate tablets.

The label contraindicates sympathomimetic supplements, hydroxytryptophan, tryptophan and SAM-e; it names St. John's wort in the serotonin-syndrome warning and lists excessive caffeine among exposures to avoid.

How this applies: Primary authority for exact tranylcypromine tablet precautions. Named supplements and class-based applications are kept distinct.

A labeled contraindication is not a measurement of the frequency of an event with each product; L-tyrosine and Panax ginseng are not individually named.

Source 2: Federal botanical safety information

nccih.nih.gov · Source check Sep 10, 2026

Population: People using Hypericum perforatum products.

The source warns about serious serotonin-related effects when combined with certain antidepressants.

How this applies: Does not give a quantified exact phenelzine or tranylcypromine risk. Other drug-metabolism interactions are not automatically transferred to these MAOIs.

Does not give a quantified exact phenelzine or tranylcypromine risk. Other drug-metabolism interactions are not automatically transferred to these MAOIs.

Research assessment: · Open full citations ↗

Review and change history

Publication status
Published research summary
Clinical review
Not yet recorded
DateUpdate
Article prepared
Initial targeted research draft. Inspected source material, adjudicated the current checker statements, and recorded preparation limits. Clinical review has not occurred.
Research summary published

Article revision: 2119e141e26174bd

This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.

Full citations require verification. Reading this answer and the source summaries does not.

Taking other supplements or medications?

Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.

Open the interaction checker

Information, not medical advice. Do not change prescribed treatment based on this guide.